127 related articles for article (PubMed ID: 16126281)
1. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.
Buttmann M; Goebeler M; Toksoy A; Schmid S; Graf W; Berberich-Siebelt F; Rieckmann P
J Neuroimmunol; 2005 Nov; 168(1-2):175-82. PubMed ID: 16126281
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells.
Buttmann M; Berberich-Siebelt F; Serfling E; Rieckmann P
J Vasc Res; 2007; 44(1):51-60. PubMed ID: 17167270
[TBL] [Abstract][Full Text] [Related]
3. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
4. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
[TBL] [Abstract][Full Text] [Related]
5. Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.
Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L
J Neuroimmunol; 2010 Sep; 226(1-2):150-7. PubMed ID: 20573405
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.
Buttmann M; Merzyn C; Rieckmann P
J Neuroimmunol; 2004 Nov; 156(1-2):195-203. PubMed ID: 15465611
[TBL] [Abstract][Full Text] [Related]
8. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Jensen J; Krakauer M; Sellebjerg F
Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
[TBL] [Abstract][Full Text] [Related]
10. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
11. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
12. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
13. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
14. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis.
Tanuma N; Sakuma H; Sasaki A; Matsumoto Y
Acta Neuropathol; 2006 Aug; 112(2):195-204. PubMed ID: 16733654
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
[TBL] [Abstract][Full Text] [Related]
16. Interferon inhibitory activity in patients with multiple sclerosis.
Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
[TBL] [Abstract][Full Text] [Related]
18. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
[TBL] [Abstract][Full Text] [Related]
19. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
Ball NJ; Cowan BJ; Hashimoto SA
J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
